Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 12, 2016 1:44 AM ET


Company Overview of Knopp Biosciences LLC

Company Overview

Knopp Biosciences LLC engages in the discovery and development of drugs for the treatments of neurological disorders. It offers KNS-760704, a drug candidate for the treatment of amyotrophic lateral sclerosis. Knopp Biosciences LLC was founded in 2010 and is based in Pittsburgh, Pennsylvania.

2100 Wharton Street

Suite 615

Pittsburgh, PA 15203

United States

Founded in 2010





Key Executives for Knopp Biosciences LLC

Chief Executive Officer, President and Member of The Board of Directors
Evp, Corporate Operations & Finance and Member of The Board of Directors
Chief Operating Officer and Senior Vice President of Clinical Research & Business Operations
Head of Clinical and Translational Medicine
Evp, Business Development & Public Affairs and Member of The Board of Directors
Compensation as of Fiscal Year 2015.

Knopp Biosciences LLC Key Developments

Calman Prussin Joins Knopp Biosciences to Lead Clinical Development of Dexpramipexole in Eosinophilic Asthma

Knopp Biosciences LLC announced that Calman Prussin, M.D. has joined Knopp to head clinical and translational medicine in immunology. In this capacity, Dr. Prussin will lead clinical development of dexpramipexole in asthma and other allergic diseases characterized by elevated eosinophils, which are white bloods cells associated with inflammation. Dexpramipexole is an oral small molecule demonstrated in ongoing clinical trials to lower levels of eosinophils in blood and inflamed tissues. Dr. Prussin comes to Knopp from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). He has acted as principal investigator in numerous clinical trials in eosinophil-associated diseases, served on the Pulmonary-Allergy Drugs Advisory Committee of the Food and Drug Administration, and is the author of 100 peer-reviewed research papers, review articles, book chapters, and abstracts. He remains a director of the American Board of Allergy and Immunology.

Knopp Biosciences LLC Collaborate with National Institute of Allergy and Infectious Diseases to Investigate on Hypereosinophilic Syndrome Studies

Knopp Biosciences LLC has announced a second collaboration with the National Institute of Allergy and Infectious Diseases, (NIAID), to investigate the eosinophil-lowering effects of the investigational drug dexpramipexole. Execution of the latest Cooperative R&D Agreement (CRADA) between Knopp and NIAID follows an agreement announced in January under which NIAID will sponsor a Phase II proof-of-concept clinical trial of dexpramipexole in hypereosinophilic syndrome (HES). Taken together, the agreements span the preclinical and clinical evaluation of dexpramipexole as a potential treatment for diseases characterized by elevated eosinophils, a type of white blood cell. Multiple clinical studies have shown that dexpramipexole reduces blood eosinophils in patients with amyotrophic lateral sclerosis (ALS). In addition, a reduction of blood eosinophils has been demonstrated in preclinical studies of dexpramipexole. These results are the basis for the hypothesis that dexpramipexole may be a potential treatment for diseases characterized by elevated eosinophils, for which off-label corticosteroid administration generally remains first-line treatment. The principal goals of the latest CRADA are to further elucidate the mechanistic effects of dexpramipexole administration in hypereosinophilic mice in vivo and to evaluate the drug's interactions with eosinophil progenitors in tissue culture. The manner in which dexpramipexole reduces eosinophil counts in animals may help guide translational studies in eosinophil-related human disease.

Similar Private Companies By Industry

Company Name Region
Anza Therapeutics, Inc. United States
Haus Bioceuticals Inc United States
Maryland Progressive Health, LLC United States
Obagi Medical Products, Inc. United States
Mills Biopharmaceuticals LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Knopp Biosciences LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at